Klaria Pharma Holding AB (FRA:6FN) Other Stockholders Equity: €-0.01 Mil (As of Mar. 2026)


FRA:6FN Klaria Pharma Holding AB FRA:6FN
7 GF Score
Price €0.06
GF Value €0.02
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Klaria Pharma Holding AB Other Stockholders Equity?

Klaria Pharma Holding AB FRA:6FN -0.66% 7 Other Stockholders Equity is €-0.01 Mil as of Mar. 2026. GuruFocus rates FRA:6FN with a GF Score™ of 7/100 and a GF Value™ of €0.02 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Klaria Pharma Holding AB's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €-0.01 Mil.

Klaria Pharma Holding AB's quarterly Other Stockholders Equity increased from Sep. 2025 (€-0.02 Mil) to Dec. 2025 (€-0.02 Mil) and increased from Dec. 2025 (€-0.02 Mil) to Mar. 2026 (€-0.01 Mil).

Klaria Pharma Holding AB's annual Other Stockholders Equity declined from Dec. 2023 (€-0.01 Mil) to Dec. 2024 (€-0.01 Mil) and declined from Dec. 2024 (€-0.01 Mil) to Dec. 2025 (€-0.02 Mil).

Klaria Pharma Holding AB Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Klaria Pharma Holding AB's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klaria Pharma Holding AB Other Stockholders Equity Chart

Klaria Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 -0.01 -0.01 -0.02

Klaria Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.02 -0.02 -0.01
FRA:6FN
7GF Score
Klaria Pharma Holding AB FRA:6FN
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Klaria Pharma Holding AB Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-0.01 Mil mean?
Klaria Pharma Holding AB (FRA:6FN) has a Other Stockholders Equity of €-0.01 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Klaria Pharma Holding AB and its competitors.
Is Klaria Pharma Holding AB's Other Stockholders Equity too high?
Klaria Pharma Holding AB's current Other Stockholders Equity is €-0.01 Mil. Overall, Klaria Pharma Holding AB has a GF Score™ of 7/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Klaria Pharma Holding AB's Other Stockholders Equity compare to ZTS and UTHR?
Klaria Pharma Holding AB's Other Stockholders Equity of €-0.01 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Klaria Pharma Holding AB and its competitors. Klaria Pharma Holding AB's current Other Stockholders Equity is €-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klaria Pharma Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Klaria Pharma Holding AB (FRA:6FN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.02, compared to a current price of €0.06 — trading 202% above its estimated fair value. The current Other Stockholders Equity is €-0.01 Mil. Klaria Pharma Holding AB's overall GF Score™ is 7/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Klaria Pharma Holding AB (FRA:6FN), the current Other Stockholders Equity is €-0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?

Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued. The current stock price of €0.06 is trading 202% above its estimated GF Value™ of €0.02. GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.

Key valuation signals for FRA:6FN:

  • Other Stockholders Equity: €-0.01 Mil
  • GF Value™: €0.02 vs. price of €0.06 (202% above fair value)
  • GF Score™: 7/100 with 6 warning signs

No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Klaria Pharma Holding AB Business Description

Other Exchanges KLAR:Sweden
Address Virdings Alle 2, Uppsala, CHE, 754 50
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
7GF Score

Get the complete analysis for FRA:6FN

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price
€0.02
GF Value